Sterling Pharma Solutions Expands Early Phase Development Capabilities at Cary, NC, Facility

Sterling Pharma Solutions, a global contract development and manufacturing organization, recently announced it has commenced a $2.1-million expansion project to increase chemical and analytical capabilities at its facility in Cary, NC.

The project will include the construction of five new laboratories: two of which will be dedicated to research and development; a scale-up chemical synthesis laboratory; as well as Quality Control and analytical services laboratories. All work is due to be completed by the end of 2022, and will allow the recruitment of up to 20 additional scientists at the facility.

“This investment will see the Cary facility expand to meet the growing demands that we are witnessing from customers looking to progress novel small molecule therapeutics, and to accelerate early-phase development of candidates towards the clinic,” said Mathew Minardi, Executive Vice President and Site Head. “Our location, in the heart of Research Triangle Park, means we are close to a hub of local innovators looking for partners to assist in development, as well as serving a wider customer base through Sterling’s global network.”

This announcement follows several investments in Sterling’s manufacturing capabilities in 2021, as well as the acquisition of its Germantown site in Wisconsin from Alcami in 2020, and a dedicated antibody-drug conjugate facility in Deeside, UK in 2021.

Sterling’s 27,000-sq-ft facility in Cary opened in 1994 and employs 50 people. It provides services to support API development and manufacturing product from pre-clinical through to Phase 2, including cGMP manufacturing, and capabilities to handle DEA schedule 1-5 controlled substances.

 Sterling Pharma Solutions is a global contract development and manufacturing organization (CDMO) with more than 50 years of experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API challenges from proof-of-concept to commercial manufacture, as well as antibody-drug conjugate (ADC) research and development bioconjugation services. Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, NC, and Germantown, WI. Find out more